ECSP18003372A - Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa - Google Patents

Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa

Info

Publication number
ECSP18003372A
ECSP18003372A ECIEPI20183372A ECPI201803372A ECSP18003372A EC SP18003372 A ECSP18003372 A EC SP18003372A EC IEPI20183372 A ECIEPI20183372 A EC IEPI20183372A EC PI201803372 A ECPI201803372 A EC PI201803372A EC SP18003372 A ECSP18003372 A EC SP18003372A
Authority
EC
Ecuador
Prior art keywords
compounds
phosphodiesterase inhibitors
tricyclic compounds
methods
inventions
Prior art date
Application number
ECIEPI20183372A
Other languages
English (en)
Inventor
Thomas Allen Chappie
Travis T Wager
Patrick Verhoest
Christopher John Helal
Ramalakshmi Yegna Chandrasekaran
Simone Sciabola
Nandini Chaturbhai Patel
Erik Alphie Lachapelle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP18003372A publication Critical patent/ECSP18003372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I o una sal farmacéuticamente aceptable del mismo, en donde los sustituyentes A, R1, R2, R3a, R3b, R4a, R4b y n son como se define en el presente documento. Las invenciones también se refieren a composiciones farmacéuticas que comprenden los compuestos, métodos de tratamiento que usan los compuestos y métodos de preparación de los compuestos.
ECIEPI20183372A 2015-06-17 2018-01-16 Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa ECSP18003372A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562180815P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
ECSP18003372A true ECSP18003372A (es) 2018-07-31

Family

ID=56418558

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20183372A ECSP18003372A (es) 2015-06-17 2018-01-16 Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa

Country Status (29)

Country Link
US (3) US11472805B2 (es)
EP (2) EP3766885B1 (es)
JP (1) JP6827959B2 (es)
KR (2) KR20180004817A (es)
CN (1) CN107787322B (es)
AU (2) AU2016280137B2 (es)
BR (1) BR112017026191B1 (es)
CA (1) CA2989456C (es)
CO (1) CO2017012994A2 (es)
CR (1) CR20170572A (es)
CU (1) CU20170153A7 (es)
DK (2) DK3766885T3 (es)
DO (1) DOP2017000297A (es)
EA (1) EA039714B1 (es)
EC (1) ECSP18003372A (es)
ES (2) ES2924371T3 (es)
HK (2) HK1245790A1 (es)
HU (2) HUE051898T2 (es)
IL (1) IL255444B (es)
MX (1) MX2017016149A (es)
PE (1) PE20180478A1 (es)
PH (1) PH12017502260A1 (es)
PL (2) PL3310784T3 (es)
PT (2) PT3766885T (es)
SG (1) SG10201912333PA (es)
TN (1) TN2017000485A1 (es)
TW (1) TWI623538B (es)
UA (1) UA125334C2 (es)
WO (1) WO2016203347A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107787322B (zh) * 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
CN109438448B (zh) * 2018-11-07 2021-08-27 成都大学 一种吲哚并七元环化合物及其制备方法和用途
JP2022518292A (ja) * 2019-01-23 2022-03-14 パス セラピューティクス，インク． ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
IL293240A (en) * 2019-11-25 2022-07-01 Alkermes Inc Transmutable macrocyclic compounds, preparations containing them and their uses
WO2022026417A1 (en) * 2020-07-26 2022-02-03 Intra-Cellular Therapies, Inc. Novel uses
US11999694B2 (en) 2021-10-29 2024-06-04 Sensorium Therapeutics, Inc. Delivery of therapeutic alkaloid compounds
WO2023076547A1 (en) * 2021-10-29 2023-05-04 Sensorium Therapeutics, Inc. Deuterated forms of alkaloid compounds and therapeutic uses thereof
WO2024118524A1 (en) * 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702321A (en) * 1968-02-13 1972-11-07 Sumitomo Chemical Co Process for preparing benzodiazepine derivatives
DE2005845A1 (de) 1969-02-12 1970-09-03 Sumitomo Chemical Company, Ltd., Osaka (Japan) Verfahren zur Herstellung von Benzodiazepinen und ihren Salzen
CH560201A5 (en) 1969-03-11 1975-03-27 Hoffmann La Roche 1 4-benzodiazepin derivs anti-convulsive, - muscle relaxant, tranquillising
AT299964B (de) * 1969-04-14 1972-07-10 Sumitomo Chemical Co Verfahren zur Herstellung neuer [2-(Dioxo-piperazino)-benzoyl]-pyridinderivate bzw. von Salzen hievon
DE2144272A1 (en) * 1971-09-03 1972-03-23 Sumitomo Chemical Co Ltd , Osaka (Japan) Nitro-benzodiazepines - prepn from 2-(2,3-diketopiperazino) nitrobenzophenones
US4022778A (en) * 1971-11-05 1977-05-10 American Home Products Corporation 10-Aryl-1,2,3,4-tetrahydropyrazino(1,2-α)indole and derivatives thereof
JPS5033259B2 (es) * 1972-03-31 1975-10-29
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP2305709A1 (en) 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
IT1313593B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DK1481992T3 (en) 2000-02-24 2017-01-30 Washington Univ St Louis Humanized antibodies which sequester amyloid beta peptide
MXPA03000906A (es) 2000-07-31 2005-02-24 Hoffmann La Roche Derivados de piperazina.
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002042429A2 (en) 2000-11-03 2002-05-30 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002100350A2 (en) 2001-06-13 2002-12-19 The Regents Of University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
EP1285922A1 (en) * 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
AU2003248354A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Acc inhibitors
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
JP2006519762A (ja) 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
FR2853329B1 (fr) 2003-04-02 2006-07-14 Onera (Off Nat Aerospatiale) Procede pour former sur un metal un revetement protecteur contenant de l'aluminium et du zirconium
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
WO2005080361A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
ATE437870T1 (de) 2004-05-12 2009-08-15 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
NZ555491A (en) 2005-01-03 2010-01-29 Univ Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
EP1779849A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
WO2007122466A1 (en) 2006-04-21 2007-11-01 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
MX2009005604A (es) 2006-11-29 2009-06-08 Pfizer Prod Inc Inhibidores espiro cetona de acetil-coa carboxilasa.
CA2676456C (en) 2007-01-22 2012-03-27 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR101709141B1 (ko) * 2008-01-25 2017-02-22 브이티브이 테라퓨틱스 엘엘씨 ＴＮＦ-α 합성의 조절자 및 ＰＤＥ4 억제제로서 3고리 화합물
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
PE20110288A1 (es) 2008-08-28 2011-05-26 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
BRPI1013246B1 (pt) 2009-03-11 2019-10-01 Pfizer, Inc. Derivados de benzofuranila, suas composições farmacêuticas e seus usos
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
PE20120399A1 (es) 2009-06-05 2012-04-24 Pfizer Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
EP2831080B1 (en) * 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
WO2013163239A1 (en) * 2012-04-26 2013-10-31 Francis Xavier Tavares Synthesis of lactams
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
CN108434149B (zh) 2013-03-15 2021-05-28 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
CN111772834B (zh) 2014-03-21 2022-07-15 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
CN107787322B (zh) * 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
AU2017223132B2 (en) * 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Also Published As

Publication number Publication date
EA039714B1 (ru) 2022-03-03
HK1254661A1 (zh) 2019-07-26
ES2924371T3 (es) 2022-10-06
PL3766885T3 (pl) 2022-09-19
CN107787322B (zh) 2023-07-07
AU2021200232A1 (en) 2021-03-18
CA2989456A1 (en) 2016-12-22
SG10201912333PA (en) 2020-02-27
EP3310784A1 (en) 2018-04-25
DK3766885T3 (da) 2022-08-01
TW201712013A (zh) 2017-04-01
TWI623538B (zh) 2018-05-11
KR102426986B1 (ko) 2022-07-28
KR20200058599A (ko) 2020-05-27
HK1245790A1 (zh) 2018-08-31
IL255444B (en) 2021-02-28
DOP2017000297A (es) 2018-03-15
AU2016280137A1 (en) 2017-11-30
HUE051898T2 (hu) 2021-03-29
EP3766885A1 (en) 2021-01-20
PT3766885T (pt) 2022-08-09
EP3766885B1 (en) 2022-05-25
KR20180004817A (ko) 2018-01-12
CA2989456C (en) 2022-01-04
US20190263816A1 (en) 2019-08-29
WO2016203347A1 (en) 2016-12-22
CN107787322A (zh) 2018-03-09
US11472805B2 (en) 2022-10-18
CR20170572A (es) 2018-03-20
JP2018521986A (ja) 2018-08-09
ES2832893T3 (es) 2021-06-11
AU2016280137B2 (en) 2021-02-04
HUE059372T2 (hu) 2022-11-28
US20230146535A1 (en) 2023-05-11
PE20180478A1 (es) 2018-03-07
JP6827959B2 (ja) 2021-02-10
CO2017012994A2 (es) 2018-03-09
MX2017016149A (es) 2018-04-18
UA125334C2 (uk) 2022-02-23
IL255444A0 (en) 2017-12-31
DK3310784T3 (da) 2020-11-09
BR112017026191B1 (pt) 2023-10-10
EP3310784B1 (en) 2020-10-07
CU20170153A7 (es) 2018-01-10
PH12017502260A1 (en) 2018-06-11
TN2017000485A1 (en) 2019-04-12
PT3310784T (pt) 2020-11-30
BR112017026191A2 (pt) 2018-08-14
US20230002386A1 (en) 2023-01-05
EA201792425A1 (ru) 2018-05-31
PL3310784T3 (pl) 2021-03-08

Similar Documents

Publication Publication Date Title
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
SV2017005472A (es) Compuestos de triazolopirimidina y usos de los mismos
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CO2018006475A2 (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
DOP2017000034A (es) Compuestos de imidazopiridazina
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CR20160527A (es) Derivados de carboxamida
CO2019008110A2 (es) Activador de nrf2
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
ECSP18056196A (es) Derivados de indano
UY36096A (es) Inhibir el canal de iones del potencial del receptor transitorio a1
UY35792A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4